New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

B cell activation and differentiation yields plasma cells with high affinity antibodies to a given
antigen in a time-frame that allows for host protection. Although the end product is most …

Gene mutations can induce cellular alteration and malignant transformation. Development of
many types of cancer is associated with mutations in the B-raf proto-oncogene (BRAF) gene …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …

Simple Summary The bone marrow (BM) microenvironment plays a crucial role in
pathogenesis of multiple myeloma (MM), and delineation of the intracellular signaling …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype
frequently associated with immunosuppression. Clinically, patients with PBL are …

Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …

Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple
different initiating events. A recent multi-region sequencing study demonstrated spatial …

Rapid progress in genome sequencing technology has put us firmly into a postgenomic era.
A key challenge in biomedical research is harnessing genome sequence to fulfill the …